{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T09:08:45Z","timestamp":1783933725478,"version":"3.55.0"},"reference-count":81,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T00:00:00Z","timestamp":1781049600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Current Opinion in Immunology"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.coi.2026.102810","type":"journal-article","created":{"date-parts":[[2026,6,27]],"date-time":"2026-06-27T18:49:35Z","timestamp":1782586175000},"page":"102810","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Ocular sarcoidosis: from clinical signs to targeted interventions"],"prefix":"10.1016","volume":"101","author":[{"given":"Thomas","family":"El Jammal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robin","family":"Jacquot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"St\u00e9phane","family":"Abramowicz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurent","family":"Kodjikian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thibaud","family":"Mathis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasmine","family":"Serrar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucas","family":"S\u00e9journet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pascal","family":"S\u00e8ve","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.coi.2026.102810_bib1","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1016\/S0140-6736(13)60680-7","article-title":"Sarcoidosis","volume":"383","author":"Valeyre","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.coi.2026.102810_bib2","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1055\/s-0034-1381229","article-title":"Clinical presentation of sarcoidosis and diagnostic work-up","volume":"35","author":"Valeyre","year":"2014","journal-title":"Semin Respir Crit Care Med"},{"key":"10.1016\/j.coi.2026.102810_bib3","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01160-2020","article-title":"Clinical phenotypes of extrapulmonary sarcoidosis: an analysis of a French, multi-ethnic, multicentre cohort","volume":"57","author":"Lhote","year":"2021","journal-title":"Eur Respir J"},{"key":"10.1016\/j.coi.2026.102810_bib4","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaut.2024.103323","article-title":"Extrapulmonary sarcoidosis","volume":"149","author":"Spagnolo","year":"2024","journal-title":"J Autoimmun"},{"key":"10.1016\/j.coi.2026.102810_bib5","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00991-2017","article-title":"Phenotypes of organ involvement in sarcoidosis","volume":"51","author":"Schupp","year":"2018","journal-title":"Eur Respir J"},{"key":"10.1016\/j.coi.2026.102810_bib6","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1111\/j.1600-0420.2006.00791.x","article-title":"Pattern of ocular manifestations in patients with sarcoidosis in developing countries","volume":"85","author":"Khanna","year":"2007","journal-title":"Acta Ophthalmol Scand"},{"key":"10.1016\/j.coi.2026.102810_bib7","doi-asserted-by":"crossref","first-page":"9440","DOI":"10.1038\/s41598-018-27554-3","article-title":"Nationwide survey on the organ-specific prevalence and its interaction with sarcoidosis in Japan","volume":"8","author":"Hattori","year":"2018","journal-title":"Sci Rep"},{"key":"10.1016\/j.coi.2026.102810_bib8","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1016\/j.autrev.2014.04.001","article-title":"Sarcoidosis and uveitis","volume":"13","author":"Jamilloux","year":"2014","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.coi.2026.102810_bib9","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1055\/s-0040-1710536","article-title":"Ocular sarcoidosis","volume":"41","author":"S\u00e8ve","year":"2020","journal-title":"Semin Respir Crit Care Med"},{"issue":"6 Pt 2","key":"10.1016\/j.coi.2026.102810_bib10","doi-asserted-by":"crossref","first-page":"e349","DOI":"10.1016\/j.lpm.2012.04.004","article-title":"Ocular sarcoidosis","volume":"41","author":"Bodaghi","year":"2012","journal-title":"Presse Med"},{"key":"10.1016\/j.coi.2026.102810_bib11","doi-asserted-by":"crossref","first-page":"3194","DOI":"10.3390\/jcm12093194","article-title":"Sarcoidosis-related uveitis: a review","volume":"12","author":"Giorgiutti","year":"2023","journal-title":"J Clin Med"},{"key":"10.1016\/j.coi.2026.102810_bib12","doi-asserted-by":"crossref","first-page":"2495","DOI":"10.1007\/s00417-019-04415-x","article-title":"Ethnicity and association with ocular, systemic manifestations and prognosis in 194 patients with sarcoid uveitis","volume":"257","author":"Coulon","year":"2019","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"10.1016\/j.coi.2026.102810_bib13","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.ajo.2021.03.003","article-title":"Systemic associations of sarcoid uveitis: correlation with uveitis phenotype and ethnicity","volume":"229","author":"Niederer","year":"2021","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.coi.2026.102810_bib14","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/j.ajo.2021.03.047","article-title":"Classification criteria for sarcoidosis-associated uveitis","volume":"228","author":"Jabs","year":"2021","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.coi.2026.102810_bib15","first-page":"1690","article-title":"BTNL2 gene polymorphism and sarcoid uveitis","volume":"103","author":"Chaperon","year":"2019","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.coi.2026.102810_bib16","doi-asserted-by":"crossref","first-page":"e26","DOI":"10.1164\/rccm.202002-0251ST","article-title":"Diagnosis and detection of sarcoidosis. An Official American Thoracic Society Clinical Practice Guideline","volume":"201","author":"Crouser","year":"2020","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.coi.2026.102810_bib17","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.04079-2020","article-title":"ERS clinical practice guidelines on treatment of sarcoidosis","volume":"58","author":"Baughman","year":"2021","journal-title":"Eur Respir J"},{"key":"10.1016\/j.coi.2026.102810_bib18","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1136\/thoraxjnl-2019-214348","article-title":"BTS Clinical Statement on pulmonary sarcoidosis","volume":"76","author":"Thillai","year":"2021","journal-title":"Thorax"},{"key":"10.1016\/j.coi.2026.102810_sbref19","doi-asserted-by":"crossref","DOI":"10.1016\/j.rmed.2024.107562","article-title":"Role of screening for uveitis in subjects with sarcoidosis","volume":"224","author":"Koh","year":"2024","journal-title":"Respir Med"},{"key":"10.1016\/j.coi.2026.102810_bib20","doi-asserted-by":"crossref","first-page":"1936","DOI":"10.1080\/09273948.2021.1976216","article-title":"The role of screening for asymptomatic ocular inflammation in sarcoidosis","volume":"30","author":"Lee","year":"2022","journal-title":"Ocul Immunol Inflamm"},{"key":"10.1016\/j.coi.2026.102810_bib21","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1111\/aos.15749","article-title":"Low utility of ocular screening in sarcoidosis in Finland","volume":"102","author":"Joukainen","year":"2024","journal-title":"Acta Ophthalmol"},{"key":"10.1016\/j.coi.2026.102810_bib22","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1007\/s12348-011-0029-7","article-title":"Ocular disease awareness and pattern of ocular manifestation in patients with biopsy-proven lung sarcoidosis","volume":"1","author":"Pefkianaki","year":"2011","journal-title":"J Ophthalmic Inflamm Infect"},{"key":"10.1016\/j.coi.2026.102810_bib23","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1007\/BF00153496","article-title":"Risk factors for ocular sarcoidosis","volume":"72","author":"Rothova","year":"1989","journal-title":"Doc Ophthalmol"},{"key":"10.1016\/j.coi.2026.102810_bib24","doi-asserted-by":"crossref","first-page":"1418","DOI":"10.1136\/bjophthalmol-2018-313356","article-title":"Revised criteria of International Workshop on Ocular Sarcoidosis (IWOS) for the diagnosis of ocular sarcoidosis","volume":"103","author":"Mochizuki","year":"2019","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.coi.2026.102810_bib25","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/j.ajo.2021.03.047","article-title":"Classification criteria for sarcoidosis-associated uveitis","volume":"228","author":"Standardization of Uveitis Nomenclature (SUN) Working Group","year":"2021","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.coi.2026.102810_bib26","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1002\/art.20839","article-title":"Association of peripheral multifocal choroiditis with sarcoidosis: a study of thirtyseven patients","volume":"51","author":"Abad","year":"2004","journal-title":"Arthritis Care Res"},{"key":"10.1016\/j.coi.2026.102810_bib27","doi-asserted-by":"crossref","first-page":"766","DOI":"10.3390\/cells10040766","article-title":"Sarcoidosis: a clinical overview from symptoms to diagnosis","volume":"10","author":"Seve","year":"2021","journal-title":"Cells"},{"key":"10.1016\/j.coi.2026.102810_bib28","first-page":"151","article-title":"The frequency of granulomatous lacrimal gland inflammation as a cause of lacrimal gland enlargement in patients without a diagnosis of systemic sarcoidosis","volume":"32","author":"Rabinowitz","year":"2013","journal-title":"Orbit Amst Neth"},{"key":"10.1016\/j.coi.2026.102810_bib29","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1007\/s00417-012-2178-2","article-title":"Ocular sarcoidosis: when should labial salivary gland biopsy be performed?","volume":"251","author":"Bernard","year":"2013","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"10.1016\/j.coi.2026.102810_bib30","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.1136\/bjophthalmol-2011-300129","article-title":"Minor salivary gland biopsy in diagnosing ocular sarcoidosis","volume":"95","author":"Blaise","year":"2011","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.coi.2026.102810_bib31","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1097\/MCP.0000000000000892","article-title":"The role of PET in the management of sarcoidosis","volume":"28","author":"Vender","year":"2022","journal-title":"Curr Opin Pulm Med"},{"key":"10.1016\/j.coi.2026.102810_bib32","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/j.ajo.2021.03.047","article-title":"Classification criteria for sarcoidosis-associated uveitis","volume":"228","year":"2021","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.coi.2026.102810_bib33","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1007\/s10384-022-00927-y","article-title":"Clinical features of ocular sarcoidosis: severe, refractory, and prolonged inflammation","volume":"66","author":"Suzuki","year":"2022","journal-title":"Jpn J Ophthalmol"},{"key":"10.1016\/j.coi.2026.102810_bib34","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.ajo.2018.09.013","article-title":"Sarcoidosis-related uveitis: clinical presentation, disease course, and rates of systemic disease progression after uveitis diagnosis","volume":"198","author":"Ma","year":"2019","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.coi.2026.102810_bib35","doi-asserted-by":"crossref","first-page":"3357","DOI":"10.1007\/s00417-022-05701-x","article-title":"Clinical features and visual outcomes of ocular sarcoidosis at a tertiary referral center in Tokyo","volume":"260","author":"Nagahori","year":"2022","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"10.1016\/j.coi.2026.102810_sbref36","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1016\/j.ophtha.2025.10.020","article-title":"Factors associated with ocular relapse and visual prognosis in sarcoid uveitis","volume":"133","author":"Abramowicz","year":"2025","journal-title":"Ophthalmology"},{"key":"10.1016\/j.coi.2026.102810_sbref37","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1136\/bjophthalmol-2020-317354","article-title":"Recommendations for the management of ocular sarcoidosis from the International Workshop on Ocular Sarcoidosis","volume":"105","author":"Takase","year":"2021","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.coi.2026.102810_bib38","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1038\/s41584-020-0372-x","article-title":"Mechanisms of action of hydroxychloroquine and chloroquine: implications for rheumatology","volume":"16","author":"Schrezenmeier","year":"2020","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.coi.2026.102810_bib39","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1080\/09273948.2023.2165952","article-title":"Hydroxychloroquine therapy in sarcoidosis-associated uveitis","volume":"32","author":"Bert","year":"2024","journal-title":"Ocul Immunol Inflamm"},{"issue":"11","key":"10.1016\/j.coi.2026.102810_bib40","doi-asserted-by":"crossref","first-page":"2188","DOI":"10.1016\/j.ophtha.2009.04.020","article-title":"Methotrexate for ocular inflammatory diseases","volume":"116","author":"Gangaputra","year":"2009","journal-title":"Ophthalmology"},{"key":"10.1016\/j.coi.2026.102810_bib41","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/j.revmed.2023.04.002","article-title":"French recommendations for the management of non-infectious chronic uveitis","volume":"44","author":"Quartier-Dit-Maire","year":"2020","journal-title":"Rev Med Interne"},{"key":"10.1016\/j.coi.2026.102810_bib42","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/j.ophtha.2018.08.021","article-title":"Periocular triamcinolone vs. intravitreal triamcinolone vs. intravitreal dexamethasone implant for the treatment of uveitic macular edema: the PeriOcular vs. INTravitreal corticosteroids for uveitic macular edema (POINT) Trial","volume":"126","author":"Thorne","year":"2019","journal-title":"Ophthalmology"},{"key":"10.1016\/j.coi.2026.102810_bib43","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1016\/j.survophthal.2021.12.002","article-title":"Efficacy and safety of intravitreal and periocular injection of corticosteroids in noninfectious uveitis: a systematic review","volume":"67","author":"Jos\u00e9-Vieira","year":"2022","journal-title":"Surv Ophthalmol"},{"key":"10.1016\/j.coi.2026.102810_bib44","doi-asserted-by":"crossref","first-page":"1916","DOI":"10.1016\/j.ophtha.2011.07.027","article-title":"Randomized comparison of systemic anti-inflammatory therapy versus fluocinolone acetonide implant for intermediate, posterior, and panuveitis: the multicenter uveitis steroid treatment trial","volume":"118","author":"Kempen","year":"2011","journal-title":"Ophthalmology"},{"key":"10.1016\/j.coi.2026.102810_bib45","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.04079-2020","article-title":"ERS clinical practice guidelines on treatment of sarcoidosis","volume":"58","author":"Baughman","year":"2021","journal-title":"Eur Respir J"},{"key":"10.1016\/j.coi.2026.102810_bib46","doi-asserted-by":"crossref","first-page":"2772","DOI":"10.3390\/biomedicines13112772","article-title":"Navigating the therapeutic landscape of non-infectious uveitis despite major gaps","volume":"13","author":"Pleyer","year":"2025","journal-title":"Biomedicines"},{"key":"10.1016\/j.coi.2026.102810_bib47","doi-asserted-by":"crossref","first-page":"1852","DOI":"10.4103\/ijo.IJO_1548_20","article-title":"Systemic immunosuppressive therapies for uveitis in developing countries","volume":"68","author":"Agrawal","year":"2020","journal-title":"Indian J Ophthalmol"},{"key":"10.1016\/j.coi.2026.102810_sbref48","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1136\/bjo-2024-325163","article-title":"Methotrexate versus conventional disease-modifying antirheumatic drugs in the treatment of non-anterior sarcoidosis-associated uveitis","volume":"109","author":"Leclercq","year":"2024","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.coi.2026.102810_bib49","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1007\/s00417-011-1844-0","article-title":"Adalimumab successful in sarcoidosis patients with refractory chronic non-infectious uveitis","volume":"250","author":"Erckens","year":"2012","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"10.1016\/j.coi.2026.102810_bib50","doi-asserted-by":"crossref","first-page":"323","DOI":"10.2147\/TCRM.S192922","article-title":"Refractory sarcoidosis: a review","volume":"16","author":"El Jammal","year":"2020","journal-title":"Ther Clin Risk Manag"},{"key":"10.1016\/j.coi.2026.102810_bib51","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/S2213-2600(25)00338-8","article-title":"A paradigm shift in corticosteroid therapy for sarcoidosis: a World Association of Sarcoidosis and Other Granulomatous Disorders Position Paper, endorsed by the Americas Association of Sarcoidosis and Other Granulomatous Disorders","volume":"14","author":"Wells","year":"2026","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.coi.2026.102810_sbref52","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1016\/j.ophtha.2025.05.026","article-title":"Corticosteroids with or without conventional disease-modifying antirheumatic drug as first-line therapy in nonanterior sarcoidosis uveitis","volume":"132","author":"Jacquot","year":"2025","journal-title":"Ophthalmology"},{"key":"10.1016\/j.coi.2026.102810_bib53","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1378\/chest.106.1.156","article-title":"Significance of interleukin 6 in patients with sarcoidosis","volume":"106","author":"Sahashi","year":"1994","journal-title":"Chest"},{"key":"10.1016\/j.coi.2026.102810_bib54","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1093\/rheumatology\/kead373","article-title":"A double-blind, placebo-controlled, randomized withdrawal trial of sarilumab for the treatment of glucocorticoid-dependent sarcoidosis","volume":"63","author":"Baker","year":"2024","journal-title":"Rheumatology"},{"key":"10.1016\/j.coi.2026.102810_sbref55","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1016\/j.ophtha.2021.11.013","article-title":"Anti\u2013tumor necrosis factor \u03b1 versus tocilizumab in the treatment of refractory uveitic macular edema: a multicenter study from the French Uveitis Network","volume":"129","author":"Leclercq","year":"2022","journal-title":"Ophthalmology"},{"key":"10.1016\/j.coi.2026.102810_bib56","doi-asserted-by":"crossref","first-page":"A364","DOI":"10.1016\/j.revmed.2023.10.065","article-title":"Essai randomis\u00e9, multicentrique \u00e9valuant l\u2019efficacit\u00e9 et la tol\u00e9rance de l\u2019adalimumab, de l\u2019anakinra et du tocilizumab dans les uv\u00e9ites r\u00e9fractaires non infectieuses (RUBI)","volume":"44","author":"Saadoun","year":"2023","journal-title":"Rev M\u00e9d Interne"},{"key":"10.1016\/j.coi.2026.102810_sbref57","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2025.1694311","article-title":"Effectiveness and safety of tocilizumab in refractory noninfectious uveitis: a systematic review and meta-analysis","volume":"16","author":"Kang","year":"2025","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.coi.2026.102810_sbref58","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1016\/j.ophtha.2025.10.004","article-title":"Adalimumab versus conventional immunosuppression for uveitis (ADVISE) trial","volume":"133","author":"Adalimumab versus Conventional Immunosuppression for Uveitis Trial Research Group","year":"2026","journal-title":"Ophthalmology"},{"key":"10.1016\/j.coi.2026.102810_bib59","doi-asserted-by":"crossref","DOI":"10.1016\/j.rmed.2025.108301","article-title":"Management of anti-drug antibodies against TNF-inhibitors in sarcoidosis patients","volume":"247","author":"Otten","year":"2025","journal-title":"Respir Med"},{"key":"10.1016\/j.coi.2026.102810_bib60","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1080\/09273948.2025.2479802","article-title":"Effectiveness of frequently used TNF inhibitors vs. conventional immunosuppressive therapies for noninfectious uveitis","volume":"33","author":"Gangaputra","year":"2025","journal-title":"Ocul Immunol Inflamm"},{"key":"10.1016\/j.coi.2026.102810_bib61","doi-asserted-by":"crossref","first-page":"2307","DOI":"10.1080\/09273948.2025.2486371","article-title":"Influence of immunogenicity of adalimumab on prognosis of patients with non-infectious-uveitis: a systematic review","volume":"33","author":"Fern\u00e1ndez-Nogueras","year":"2025","journal-title":"Ocul Immunol Inflamm"},{"key":"10.1016\/j.coi.2026.102810_bib62","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.1136\/bjophthalmol-2021-319072","article-title":"Therapeutic drug monitoring guides the management of patients with chronic non-infectious uveitis treated with adalimumab: a retrospective study","volume":"106","author":"Sejournet","year":"2022","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.coi.2026.102810_bib63","doi-asserted-by":"crossref","first-page":"A126","DOI":"10.1016\/j.rhum.2021.10.198","article-title":"Absence d\u2019association entre la concentration du polyglutamate intra-\u00e9rythrocytaire du m\u00e9thotrexate et la r\u00e9ponse clinique au cours de la polyarthrite rhumato\u00efde (\u00e9tude POLYGLU)","volume":"88","author":"Poudret","year":"2021","journal-title":"Rev Rhum"},{"key":"10.1016\/j.coi.2026.102810_bib64","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1111\/bcp.15980","article-title":"The correlation between 4 adherence measurements methods in patients with rheumatoid arthritis using methotrexate","volume":"90","author":"Hebing","year":"2024","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.coi.2026.102810_bib65","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1093\/ibd\/izy309","article-title":"The accuracy of adherence self-report scales in patients on thiopurines for inflammatory bowel disease: a comparison with drug metabolite levels and medication possession ratios","volume":"25","author":"Selinger","year":"2019","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.coi.2026.102810_bib66","doi-asserted-by":"crossref","first-page":"1786","DOI":"10.1136\/annrheumdis-2012-202322","article-title":"Hydroxychloroquine in systemic lupus erythematosus: results of a French multicentre controlled trial (PLUS Study)","volume":"72","author":"Costedoat-Chalumeau","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.coi.2026.102810_bib67","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1111\/1756-185X.12910","article-title":"Oral Methotrexate in split dose weekly versus oral or parenteral Methotrexate once weekly in Rheumatoid Arthritis: a short-term study","volume":"21","author":"Dhaon","year":"2018","journal-title":"Int J Rheum Dis"},{"key":"10.1016\/j.coi.2026.102810_bib68","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.ophtha.2025.09.019","article-title":"Evaluating the effectiveness of escalating to weekly adalimumab dosing for the treatment of noninfectious uveitis: a multicenter study","volume":"133","author":"Pillar","year":"2026","journal-title":"Ophthalmology"},{"key":"10.1016\/j.coi.2026.102810_bib69","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1186\/s12348-023-00364-z","article-title":"Ocular sarcoidosis in adults and children: update on clinical manifestation and diagnosis","volume":"13","author":"Bazewicz","year":"2023","journal-title":"J Ophthalmic Inflamm Infect"},{"key":"10.1016\/j.coi.2026.102810_bib70","series-title":"StatPearls [Internet]","article-title":"Ocular Sarcoidosis","author":"Simakurthy","year":"2023"},{"key":"10.1016\/j.coi.2026.102810_bib71","first-page":"898","article-title":"Sarcoid uveitis: an intriguing challenger","volume":"58","author":"Allegri","year":"2022","journal-title":"Med Kaunas Lith"},{"key":"10.1016\/j.coi.2026.102810_bib72","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01482-2018","article-title":"Dramatic response of refractory sarcoidosis under ruxolitinib in a patient with associated JAK2-mutated polycythemia","volume":"52","author":"Rotenberg","year":"2018","journal-title":"Eur Respir J"},{"key":"10.1016\/j.coi.2026.102810_bib73","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1136\/annrheumdis-2019-215387","article-title":"Refractory sarcoidosis-like systemic granulomatosis responding to ruxolitinib","volume":"78","author":"Levraut","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.coi.2026.102810_bib74","article-title":"Infliximab-induced pulmonary sarcoidosis treated with upadacitinib: a case report and review of the literature","volume":"17","author":"Swe","year":"2025","journal-title":"Cureus"},{"key":"10.1016\/j.coi.2026.102810_bib75","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.jdcr.2024.06.019","article-title":"Recalcitrant cutaneous sarcoidosis treated with upadacitinib: case report","volume":"51","author":"Safadi","year":"2024","journal-title":"JAAD Case Rep"},{"key":"10.1016\/j.coi.2026.102810_bib76","doi-asserted-by":"crossref","first-page":"2540","DOI":"10.1056\/NEJMoa1805958","article-title":"Tofacitinib Treatment and Molecular Analysis of Cutaneous Sarcoidosis","volume":"379","author":"Damsky","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.coi.2026.102810_bib77","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.revmed.2024.10.452","article-title":"JAK inhibitors (JAKi): mechanisms of action and perspectives in systemic and autoimmune diseases","volume":"46","author":"Chikhoune","year":"2025","journal-title":"Rev M\u00e9d Interne"},{"key":"10.1016\/j.coi.2026.102810_sbref78","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1001\/jamaophthalmol.2024.2439","article-title":"Filgotinib in active noninfectious uveitis: the HUMBOLDT randomized clinical trial","volume":"142","author":"Srivastava","year":"2024","journal-title":"JAMA Ophthalmol"},{"key":"10.1016\/j.coi.2026.102810_bib79","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1038\/ni.3655","article-title":"Chronic signaling via the metabolic checkpoint kinase mTORC1 induces m acrophage granuloma formation and marks sarcoidosis progression","volume":"18","author":"Linke","year":"2017","journal-title":"Nat Immunol"},{"key":"10.1016\/j.coi.2026.102810_bib80","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1016\/j.ophtha.2020.03.033","article-title":"Efficacy and safety of intravitreal sirolimus for noninfectious uveitis of the posterior segment: results from the Sirolimus Study Assessing Double-Masked Uveitis Treatment (SAKURA) Program","volume":"127","author":"Merrill","year":"2020","journal-title":"Ophthalmology"},{"key":"10.1016\/j.coi.2026.102810_bib81","doi-asserted-by":"crossref","first-page":"e81","DOI":"10.1016\/S2665-9913(23)00302-8","article-title":"Efficacy and safety of mTOR inhibition in cutaneous sarcoidosis: a single-centre trial","volume":"6","author":"Redl","year":"2024","journal-title":"Lancet Rheumatol"}],"container-title":["Current Opinion in Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0952791526000877?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0952791526000877?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T08:39:57Z","timestamp":1783931997000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0952791526000877"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":81,"alternative-id":["S0952791526000877"],"URL":"https:\/\/doi.org\/10.1016\/j.coi.2026.102810","relation":{},"ISSN":["0952-7915"],"issn-type":[{"value":"0952-7915","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Ocular sarcoidosis: from clinical signs to targeted interventions","name":"articletitle","label":"Article Title"},{"value":"Current Opinion in Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.coi.2026.102810","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"102810"}}